Ensysce Biosciences (ENSC) Non Operating Interest Expenses (2020 - 2025)

Ensysce Biosciences (ENSC) has reported Non Operating Interest Expenses for 6 consecutive years, with -$992.0 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Non Operating Interest Expenses fell 109.23% year-over-year to -$992.0 in Q4 2025; TTM through Dec 2025 was $12393.0, a 99.04% decrease from a year earlier, with the FY2025 full-year figure at $12393.0, down 99.04% from the prior year.
• Non Operating Interest Expenses was -$992.0 for Q4 2025 at Ensysce Biosciences, down from $6369.0 in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $1.2 million in Q1 2024 and troughed at -$992.0 in Q4 2025.
• A 5-year average of $161137.6 and a median of $12487.0 in 2021 frame the typical range for Non Operating Interest Expenses.
• Across the five-year window, Non Operating Interest Expenses surged 83271.08% in 2024 and sank 109.23% in 2025, its largest moves.
• Over 5 years, Non Operating Interest Expenses stood at $12487.0 in 2021, then surged by 315.34% to $51863.0 in 2022, then jumped by 564.83% to $344799.0 in 2023, then tumbled by 96.88% to $10753.0 in 2024, then tumbled by 109.23% to -$992.0 in 2025.
• The last three Non Operating Interest Expenses figures came in at -$992.0 (Q4 2025), $6369.0 (Q3 2025), and $3160.0 (Q2 2025), per Business Quant data.